A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations

Detalles Bibliográficos
Autores principales: Wang, Pingli, Cao, Liming, Tian, Panwen, Ren, Shengxiang, Miao, Liyun, Zhou, Chengzhi, Fan, Yun, Li, Yuping, Lv, Dongqing, Zhao, Xin, Yang, Mei, Zhu, Chaonan, Yu, Bing, Xu, June, Song, Yong, Wang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508135/
https://www.ncbi.nlm.nih.gov/pubmed/37322852
http://dx.doi.org/10.1002/cac2.12456
Descripción
Sumario:

Ejemplares similares